Image

Global Irritable Bowel Syndrome Treatment Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Upcoming Report
  • Feb 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Feb 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Irritable Bowel Syndrome Treatment Market, By Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi and Amitiza), End Use (Hospitals, Clinics and Research Laboratories), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028

Irritable Bowel Syndrome Treatment Market Market Analysis and Insights of Global Irritable Bowel Syndrome Treatment Market

Irritable bowel syndrome treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the irritable bowel syndrome treatment market to account to USD 3,808.95 million by 2028 growing at a CAGR of 9.32% in the above-mentioned forecast period. Rising prevalence of target disease, coupled with increasing uptake of drugs for the same has been directly impacting the growth of irritable bowel syndrome treatment market.

Irritable intestinal disease is an active intestinal disease that can be characterized by a decrease in intestinal muscle. Irritable bowel syndrome affects the large intestine. Irritable bowel syndrome is associated with intestinal dysfunction and occurs more frequently in adults. Constipation, diarrhea, abdominal pain, changes in bowel movements and constipation are some of the most common symptoms of a painful bowel disease. Blood tests and endoscopy are often performed to diagnose the syndrome. Irritable bowel syndrome is a common disease. There is no complete cure for the irritating syndrome. Medications used for intestinal irritation are effective in reducing symptoms.

Rising commercialization of existing products in different regions is the main driver for the irritable bowel syndrome treatment market. Change in lifestyle and eating habits increases the incidence of this disorder that may escalate the use of this treatment which is also a driver for the irritable bowel syndrome treatment market. Increasing in levels of stress and increase in prevalence of irritable bowel syndrome in female is an opportunity for the irritable bowel syndrome treatment market.

Lack of specific treatment which treat all the symptoms of this disorder is the key factors that restrain the growth of the irritable bowel syndrome treatment market. However, higher competition among the key players in terms of pricing which act as a challenge for the growth of the irritable bowel syndrome treatment market.

This irritable bowel syndrome treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research irritable bowel syndrome treatment market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

In January 2019, AstraZeneca collaborated with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong, and China Macau for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C). IBS-C is characterized by symptoms of abdominal pain and constipation, is a prevalent functional gastrointestinal disorder in China and there are currently few treatment options for this condition. The revised agreement gives AstraZeneca sole accountability for evolving, manufacturing, and commercializing Linzess in China mainland, China Hong Kong, and China Macau.

Irritable Bowel Syndrome Treatment Market Scope and Market Size

Irritable bowel syndrome treatment market is segmented on the basis of type, product and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on type, the irritable bowel syndrome treatment market is segmented into IBS-C, IBS-D. IBS-C is further segmented into linzess/constella, amitiza and others. IBS-D is further segmented into xifaxan, viberzi and others.
  • Irritable bowel syndrome treatment market has also been segmented based on the product into xifaxan, linzess/constella, viberzi and amitiza.
  • Based on end use, the irritable bowel syndrome treatment market is segmented into hospitals, clinics and research laboratories.

Irritable Bowel Syndrome Treatment Market Country Level Analysis

Irritable bowel syndrome treatment market is analysed and market size insights and trends are provided by country, type, product and end use as referenced above.

The countries covered in the irritable bowel syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the irritable bowel syndrome treatment market due to the presence of key market players, a well-established healthcare infrastructure, greater patient awareness, and a strong presence of novel products, while Europe is expected to grow at the highest growth rate in the forecast period of 2021 to 2028 due to the presence of a large target population and rising commercialization of IBS products in the region and increasing initiatives in the region to raise awareness.

The country section of the irritable bowel syndrome treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Irritable bowel syndrome treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for irritable bowel syndrome treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the irritable bowel syndrome treatment market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Irritable Bowel Syndrome Treatment Market Share Analysis

Irritable bowel syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to irritable bowel syndrome treatment market.

The major players covered in the irritable bowel syndrome treatment market report are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals In., Bausch Health, Synthetic Biologics, Inc., Ardelyx., Salix Pharmaceuticals, Mallinckrodt., Abbott Laboratories, LEXICON PHARMACEUTICALS, INC, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Ono Pharmaceutical Co., Ltd., Pfizer Inc, Novartis, Sebela Pharmaceuticals Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-
Why Choose Us


Frequently Asked Questions